Cargando…
Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report
Advanced intrahepatic cholangiocarcinoma (iCCA) is not suitable for surgical treatment. Guided by the concept of precision medicine, preoperative systematic treatment may reshape the clinical outcomes of advanced intrahepatic cholangiocarcinoma patients. We describe the case of a 38-year-old female...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484748/ https://www.ncbi.nlm.nih.gov/pubmed/34603331 http://dx.doi.org/10.3389/fimmu.2021.744571 |
_version_ | 1784577387550212096 |
---|---|
author | Zhang, Ze Zhang, Wenwen Wang, Hongguang Hu, Bingyang Wang, Zhanbo Lu, Shichun |
author_facet | Zhang, Ze Zhang, Wenwen Wang, Hongguang Hu, Bingyang Wang, Zhanbo Lu, Shichun |
author_sort | Zhang, Ze |
collection | PubMed |
description | Advanced intrahepatic cholangiocarcinoma (iCCA) is not suitable for surgical treatment. Guided by the concept of precision medicine, preoperative systematic treatment may reshape the clinical outcomes of advanced intrahepatic cholangiocarcinoma patients. We describe the case of a 38-year-old female who has been diagnosed with stage IV intrahepatic cholangiocarcinoma with a high tumor mutational burden and positively programmed death-ligand 1 (PD-L1) expression. The patient was treated with programmed cell death 1 (PD-1) inhibitors combined with tyrosine kinase inhibitors (TKIs). After 7 cycles of combination therapy, she underwent radical resection and no tumor cells were found in the postoperative histopathological examination. In addition, the patient’s survival time had reached 25 months, as of August 2021. To date, this is the first case of successful radical resection after combined immunotherapy with TKIs for advanced PD-L1-positive intrahepatic cholangiocarcinoma with a high tumor mutational burden (TMB). The case provides a new approach to the treatment of advanced intrahepatic cholangiocarcinoma. |
format | Online Article Text |
id | pubmed-8484748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84847482021-10-02 Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report Zhang, Ze Zhang, Wenwen Wang, Hongguang Hu, Bingyang Wang, Zhanbo Lu, Shichun Front Immunol Immunology Advanced intrahepatic cholangiocarcinoma (iCCA) is not suitable for surgical treatment. Guided by the concept of precision medicine, preoperative systematic treatment may reshape the clinical outcomes of advanced intrahepatic cholangiocarcinoma patients. We describe the case of a 38-year-old female who has been diagnosed with stage IV intrahepatic cholangiocarcinoma with a high tumor mutational burden and positively programmed death-ligand 1 (PD-L1) expression. The patient was treated with programmed cell death 1 (PD-1) inhibitors combined with tyrosine kinase inhibitors (TKIs). After 7 cycles of combination therapy, she underwent radical resection and no tumor cells were found in the postoperative histopathological examination. In addition, the patient’s survival time had reached 25 months, as of August 2021. To date, this is the first case of successful radical resection after combined immunotherapy with TKIs for advanced PD-L1-positive intrahepatic cholangiocarcinoma with a high tumor mutational burden (TMB). The case provides a new approach to the treatment of advanced intrahepatic cholangiocarcinoma. Frontiers Media S.A. 2021-09-17 /pmc/articles/PMC8484748/ /pubmed/34603331 http://dx.doi.org/10.3389/fimmu.2021.744571 Text en Copyright © 2021 Zhang, Zhang, Wang, Hu, Wang and Lu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zhang, Ze Zhang, Wenwen Wang, Hongguang Hu, Bingyang Wang, Zhanbo Lu, Shichun Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report |
title | Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report |
title_full | Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report |
title_fullStr | Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report |
title_full_unstemmed | Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report |
title_short | Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report |
title_sort | successful treatment of advanced intrahepatic cholangiocarcinoma with a high tumor mutational burden and pd-l1 expression by pd-1 blockade combined with tyrosine kinase inhibitors: a case report |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484748/ https://www.ncbi.nlm.nih.gov/pubmed/34603331 http://dx.doi.org/10.3389/fimmu.2021.744571 |
work_keys_str_mv | AT zhangze successfultreatmentofadvancedintrahepaticcholangiocarcinomawithahightumormutationalburdenandpdl1expressionbypd1blockadecombinedwithtyrosinekinaseinhibitorsacasereport AT zhangwenwen successfultreatmentofadvancedintrahepaticcholangiocarcinomawithahightumormutationalburdenandpdl1expressionbypd1blockadecombinedwithtyrosinekinaseinhibitorsacasereport AT wanghongguang successfultreatmentofadvancedintrahepaticcholangiocarcinomawithahightumormutationalburdenandpdl1expressionbypd1blockadecombinedwithtyrosinekinaseinhibitorsacasereport AT hubingyang successfultreatmentofadvancedintrahepaticcholangiocarcinomawithahightumormutationalburdenandpdl1expressionbypd1blockadecombinedwithtyrosinekinaseinhibitorsacasereport AT wangzhanbo successfultreatmentofadvancedintrahepaticcholangiocarcinomawithahightumormutationalburdenandpdl1expressionbypd1blockadecombinedwithtyrosinekinaseinhibitorsacasereport AT lushichun successfultreatmentofadvancedintrahepaticcholangiocarcinomawithahightumormutationalburdenandpdl1expressionbypd1blockadecombinedwithtyrosinekinaseinhibitorsacasereport |